Tavapadon
- Generic Name
- Tavapadon
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H16F3N3O3
- CAS Number
- 1643489-24-0
- Unique Ingredient Identifier
- PT4P8MJP8L
- Background
Tavapadon is under investigation in clinical trial NCT02262767 (A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 Co-administered With Trimethobenzamide Hydrochloride in Healthy Subjects).
- Associated Conditions
- -
- Associated Therapies
- -
Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's Disease
- First Posted Date
- 2022-11-09
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 25
- Registration Number
- NCT05610189
- Locations
- 🇺🇸
South Miami, Florida, South Miami, Florida, United States
🇺🇸Hollywood, Florida, Hollywood, Florida, United States
🇺🇸Farmington Hills, Michigan, Farmington Hills, Michigan, United States
Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult Participants
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-04-20
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT05581823
- Locations
- 🇺🇸
Madison, Wisconsin, Madison, Wisconsin, United States
To Evaluate the Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Mild and Moderate Hepatic Impairment Compared to Participants With Normal Hepatic Function
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2023-05-30
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT05404529
- Locations
- 🇺🇸
Miami, Florida, Miami, Florida, United States
🇺🇸Orlando, Florida, Orlando, Florida, United States
🇺🇸San Antonio, Texas, San Antonio, Texas, United States
To Evaluate Pharmacokinetics (PK) and Safety of Tavapadon in Participants With Severe Renal Impairment Compared to Participants With Normal Renal Function
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 14
- Registration Number
- NCT05404542
- Locations
- 🇺🇸
Jacksonville, Florida, Jacksonville, Florida, United States
🇺🇸Tampa, Florida, Tampa, Florida, United States
🇺🇸Miami, Florida, Miami, Florida, United States
Open-label Trial in Parkinson's Disease (PD)
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 992
- Registration Number
- NCT04760769
- Locations
- 🇺🇸
Pheonix, Arizona, Phoenix, Arizona, United States
🇺🇸Reseda, California, Reseda, California, United States
🇺🇸Naples, Florida, Naples, Florida, United States
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 507
- Registration Number
- NCT04542499
- Locations
- 🇺🇸
Chicago, Illinois, Chicago, Illinois, United States
🇺🇸Boston, Massachusettes, Boston, Massachusetts, United States
🇺🇸Cleveland, Ohio, Cleveland, Ohio, United States
Flexible-Dose Trial in Early Parkinson's Disease (PD)
- First Posted Date
- 2020-01-10
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 304
- Registration Number
- NCT04223193
- Locations
- 🇦🇺
Macquarie Park, New South Wales, Sydney, New South Wales, Australia
🇺🇸Fresno, California, Fresno, California, United States
🇺🇸Boca Raton, Florida, Boca Raton, Florida, United States
Fixed-Dose Trial in Early Parkinson's Disease (PD)
- First Posted Date
- 2019-12-17
- Last Posted Date
- 2024-07-29
- Lead Sponsor
- Cerevel Therapeutics, LLC
- Target Recruit Count
- 522
- Registration Number
- NCT04201093
- Locations
- 🇺🇸
Englewood, Colorado, Englewood, Colorado, United States
🇺🇸Boca Raton, Florida, Boca Raton, Florida, United States
🇺🇸Scarborough, Maine, Scarborough, Maine, United States
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients at Early Stage of the Disease
- First Posted Date
- 2016-07-28
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 57
- Registration Number
- NCT02847650
- Locations
- 🇺🇸
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton, Florida, United States
🇺🇸Asheville Neurology Specialists PA, Asheville, North Carolina, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of PF-06649751 in Subjects With Idiopathic Parkinson's Disease
- Conditions
- Interventions
- First Posted Date
- 2015-02-26
- Last Posted Date
- 2023-09-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT02373072
- Locations
- 🇺🇸
Walnut Hill Medical Center, Dallas, Texas, United States
🇺🇸Collaborative Neuroscience Network, LLC., Long Beach, California, United States
🇺🇸Parkinson's Movement Disorder Center of Maryland, Elkridge, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.